Multidisciplinary treatment and neoadjuvant therapy of pancreatic cancer
10.3760/cma.j.cn115667-20200831-00142
- VernacularTitle:胰腺癌MDT诊治与新辅助治疗
- Author:
Shuo SHEN
1
;
Shiwei GUO
;
Suizhi GAO
;
Xiaohan SHI
;
Bo LI
;
Guoxiao ZHANG
;
Yun BIAN
;
Hui JIANG
;
Kaixuan WANG
;
Gang JIN
Author Information
1. 海军军医大学第一附属医院肝胆胰脾外科，上海 200433
- From:
Chinese Journal of Pancreatology
2020;20(5):338-341
- CountryChina
- Language:Chinese
-
Abstract:
As a new direction of pancreatic cancer treatment, neoadjuvant therapy for pancreatic cancer has been confirmed to be able to improve the prognosis of the patients. Under multidisciplinary treatment (MDT) mode, neoadjuvant therapy combines multidisciplinary advantages to solve patients′ problems of diagnosis and treatment, provides accurate, comprehensive and individual treatments, and maximizes the clinical benefit for patients. In this article, we summarize the present problems of neoadjuvant therapy for pancreatic cancer in patient selection, treatment regimen selection, treatment response evaluation and surgical selection, and explore the direction of clinical research and neoadjuvant therapy for pancreatic cancer under MDT mode.
